Please provide your email address to receive an email when new articles are posted on . Oral testosterone undecanoate is an effective long-term therapy for men with hypogonadism, with a safety profile ...
Pharmaceutical Technology on MSN
Apotex and Grünenthal sign deal for Nebido Canadian distribution
Apotex’s Searchlight Pharma will seek marketing authorisation and manage commercialisation activities for Nebido in Canada.
- Launched in 2020, JATENZO was the first oral softgel testosterone medicine approved in the US by the FDA in more than 60 years- JATENZO is an oral softgel testosterone undecanoate for testosterone ...
Please provide your email address to receive an email when new articles are posted on . The FDA has approved an oral testosterone undecanoate softgel for men with deficiency or absence of endogenous ...
Apotex Inc. ("Apotex"), the largest Canadian-based pharmaceutical company, and Grünenthal, a global leader in pain management ...
TORONTO—Testosterone undecanoate administered every three months is a safe treatment for hypogonadal men, according to a four-year study. Parenteral testosterone undecanoate (TU) was administered to ...
MIAMI -- Oral testosterone replacement therapy (TRT) seemed safe and effective in men with testosterone deficiency, according to a meta-analysis. Among nine studies that looked at changes in serum ...
RALEIGH, N.C., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals, Inc. today announced the company will initiate a new post-marketing clinical study for potential label expansion evaluating ...
RALEIGH, N.C., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals, Inc. a patient-centric healthcare company committed to advancing innovative therapies for testosterone deficiency, today ...
"Combined Clomiphene and High-Dose Oral Testosterone Therapy in Hypogonadal Men: A Case Series" – This study, conducted by Dr. Andrew Sun, Grace Yoon BS, and Jimmy Vo BS, explores the effects of ...
RALEIGH, N.C., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals, Inc. today announced the company will initiate a new post-marketing clinical study for potential label expansion evaluating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results